This company has been marked as potentially delisted and may not be actively trading. Flexion Therapeutics (FLXN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsSustainabilityTrendsBuy This Stock FLXN vs. MENS, MOR, GMTX, CALT, ZYME, MBX, SBTX, AVTE, BIOA, and NLTXShould you be buying Flexion Therapeutics stock or one of its competitors? The main competitors of Flexion Therapeutics include Jyong Biotech (MENS), MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), and Neoleukin Therapeutics (NLTX). Flexion Therapeutics vs. Its Competitors Jyong Biotech MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Silverback Therapeutics Aerovate Therapeutics BioAge Labs Neoleukin Therapeutics Flexion Therapeutics (NASDAQ:FLXN) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Do insiders and institutionals believe in FLXN or MENS? 90.0% of Flexion Therapeutics shares are held by institutional investors. 9.1% of Flexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor FLXN or MENS? In the previous week, Jyong Biotech had 3 more articles in the media than Flexion Therapeutics. MarketBeat recorded 3 mentions for Jyong Biotech and 0 mentions for Flexion Therapeutics. Jyong Biotech's average media sentiment score of 0.73 beat Flexion Therapeutics' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment Flexion Therapeutics Neutral Jyong Biotech Positive Which has preferable earnings and valuation, FLXN or MENS? Jyong Biotech has lower revenue, but higher earnings than Flexion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlexion Therapeutics$85.55M15.03-$113.71M-$2.01-12.71Jyong BiotechN/AN/AN/AN/AN/A Is FLXN or MENS more profitable? Jyong Biotech has a net margin of 0.00% compared to Flexion Therapeutics' net margin of -100.32%. Company Net Margins Return on Equity Return on Assets Flexion Therapeutics-100.32% N/A -44.26% Jyong Biotech N/A N/A N/A SummaryJyong Biotech beats Flexion Therapeutics on 4 of the 7 factors compared between the two stocks. Get Flexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLXN vs. The Competition Export to ExcelMetricFlexion TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$736.37M$5.84B$10.14BDividend YieldN/A4.84%5.68%4.60%P/E Ratio-12.711.1775.4125.98Price / Sales15.0326.64515.81181.13Price / CashN/A19.5637.5660.44Price / Book-75.156.6812.156.29Net Income-$113.71M-$4.13M$3.29B$271.07M Flexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLXNFlexion TherapeuticsN/A$25.550.0%N/AN/A$1.29B$85.55M-12.71257MENSJyong BiotechN/A$59.80+9.1%N/AN/A$4.17BN/A0.0031News CoverageGap DownMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.650.0%N/A+23.9%$2.58BN/A-59.6530CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageZYMEZymeworks2.3753 of 5 stars$14.01-5.4%$21.43+53.0%+25.5%$1.05B$122.87M-9.34460Positive NewsMBXMBX Biosciences2.8351 of 5 stars$14.57-3.4%$37.63+158.2%N/A$489.47MN/A-3.2136News CoveragePositive NewsSBTXSilverback TherapeuticsN/A$11.62-9.6%N/A-20.6%$418.99MN/A-4.8083News CoverageHigh Trading VolumeAVTEAerovate TherapeuticsN/A$7.90-2.2%N/A-88.4%$228.98MN/A-2.6420Positive NewsHigh Trading VolumeBIOABioAge Labs0.1283 of 5 stars$4.65-5.7%N/AN/A$176.74MN/A0.00N/APositive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$18.48-1.9%N/A-54.7%$173.68MN/A-5.9490 Related Companies and Tools Related Companies MENS Alternatives MOR Alternatives GMTX Alternatives CALT Alternatives ZYME Alternatives MBX Alternatives SBTX Alternatives AVTE Alternatives BIOA Alternatives NLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLXN) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flexion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FLXN Stock Alerts